Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Boston Beer Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.63 (market cap $29.60B), while Boston Beer Company Inc trades at $180.23 (market cap $1.86B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.9× Boston Beer Company Inc's market cap, and Boston Beer Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SAM | |
|---|---|---|
Market Cap | $29.60B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $260.05 |
52-Week Low | $205.48 | $161.08 |
Enterprise Value | $27.56B | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Boston Beer Company (SAM) trades at $181.95, up 0.53% with bearish technical signals despite recent earnings volatility. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but faces profitability challenges with negative net income margin (-3.64%) and ROE (-8.61%). Recent Q2 2026 earnings missed estimates at $3.65 vs. $4.83 expected, while operating cash flow remains strong at $270M in 2025. Analyst sentiment is cautious with 72% hold ratings amid declining volumes and competitive pressures.
Outlook remains challenging with weak demand impacting core brands, though spirits-based RTD growth and margin improvements offer some support. The consensus price target of $207.33 suggests 14% upside potential, but investors face risks from sustained volume declines, rising marketing costs, and negative earnings growth projections for 2026. The stock's current technical position near pivot point resistance at $182 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
